NTHI logo

NEONC TECHNOLOGIES HOLDINGS

NTHINASDAQ
πŸ† #4202 by market capUS Equity
$744.06β–² $50.15 (+6.74%)
Simulated price
πŸ””
Track NTHI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 6.7%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$82M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
76
Good
No chart data available for NTHI.

Trading Snapshot

Day Range
$738.02 – $752.06
52-Week Range
$2.96 – $12.99
Volume
$2.33B
Avg Volume
$2.32B
Shares Outstanding
25.9M
Next Earnings
Dec 12, 2026

Fundamentals Snapshot

Annual Revenue
$39,990
Last Q Revenue
$9,176
P/E Ratio
-1.4
P/S Ratio
0.0x
EPS (TTM)
$-1.91
Dividend Yield
0.00%

Why Investors Own NTHI

  • βœ“High-growth profile β€” revenue up +32.9% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 54% gross margin and 17% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NTHI logo

NEONC TECHNOLOGIES HOLDINGS

NTHI
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$39,990β–² +38.3% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
54.3%β–² +3.6% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$7,078β–² +38.3% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$6,718β–² +38.3% YoY
StockOtter Β· stockotter.space

About NEONC TECHNOLOGIES HOLDINGS

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Price Target

β“˜
Average Target
$813.45
β–² +9.3% Upside
High Target$920.91
Low Target$739.67
Based on 14 analysts

Latest News & Updates